Related Experiment Videos
Effect of piroxicam on matrix metalloproteinase 2 and apoptosis
A Mirshafiey1, F Vaezzadeh, M R Khorramizadeh
1Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran. a_mirshafiey@yahoo.com
Abstract:
We examined the effect of a nonsteroidal anti-inflammatory drug (NSAID), piroxicam, on apoptosis and matrix metalloproteinase 2 (MMP-2) activity compared with diclofenac and dexamethasone. The fibrosarcoma (WEHI-164) cell line was used to assess tolerability, MMP-2 activity and apoptosis. Piroxicam, dexamethasone and diclofenac were used at concentrations of 10-200 microg/ml in triplicate and 2-fold dilutions. MMP-2 activity was assessed using zymography. For assessment of apoptosis, the terminal deoxyribonucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) method was used. The results of this study show that piroxicam is able to diminish MMP-2 activity and induce apoptosis under in vitro conditions. Piroxicam also showed high tolerability compared with diclofenac and dexamethasone. In conclusion, piroxicam is able to induce apoptosis and suppress MMP-2 activity.
Insights
Piroxicam, a nonsteroidal anti-inflammatory drug (NSAID), effectively reduces matrix metalloproteinase 2 (MMP-2) activity and promotes apoptosis in fibrosarcoma cells. It demonstrated superior tolerability compared to diclofenac and dexamethasone.
Area of Science:
- Pharmacology
- Cancer Biology
- Cellular Biology
Background:
- Nonsteroidal anti-inflammatory drugs (NSAIDs) are widely used for their anti-inflammatory properties.
- Matrix metalloproteinase 2 (MMP-2) plays a role in tumor invasion and metastasis.
- Apoptosis, or programmed cell death, is a critical mechanism for controlling cell proliferation.
Purpose of the Study:
- To investigate the effects of piroxicam on apoptosis and MMP-2 activity in fibrosarcoma cells.
- To compare the efficacy and tolerability of piroxicam with diclofenac and dexamethasone.
- To evaluate piroxicam's potential as an anti-cancer agent.
Main Methods:
- Utilized the WEHI-164 fibrosarcoma cell line for in vitro experiments.
- Assessed MMP-2 activity using zymography.
- Quantified apoptosis via the terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) assay.
- Administered drugs at concentrations ranging from 10-200 microg/ml with 2-fold serial dilutions.
Main Results:
- Piroxicam significantly diminished MMP-2 activity in fibrosarcoma cells.
- Piroxicam treatment led to a notable induction of apoptosis.
- Piroxicam exhibited higher tolerability compared to diclofenac and dexamethasone.
Conclusions:
- Piroxicam demonstrates the capacity to induce apoptosis and suppress MMP-2 activity.
- These findings suggest piroxicam's potential therapeutic value in managing fibrosarcoma.
- Piroxicam presents a favorable tolerability profile for potential clinical application.
Related Concept Videos
Role of Matrix Metalloproteases in Degradation of ECM
A...
The Intrinsic Apoptotic Pathway
Caspases